Prosecution Insights
Last updated: November 04, 2026
Application No. 17/434,624

PHARMACEUTICAL COMPOSITION COMPRISING TBN, OR SALT OR HYDRATE THEREOF, AND PREPARATION METHOD THEREOF

Final Rejection §112
Filed
Aug 27, 2021
Priority
Feb 27, 2019 — CN 201910143739.0 +1 more
Examiner
MOU, LIYUAN
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Guangzhou Magpie Pharmaceuticals Co. Ltd.
OA Round
4 (Final)
44%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
53 granted / 121 resolved
-16.2% vs TC avg
Strong +60% interview lift
Without
With
+59.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
82 currently pending
Career history
215
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
35.9%
-4.1% vs TC avg
§102
14.0%
-26.0% vs TC avg
§112
25.4%
-14.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 121 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Response to Amendment Acknowledgment is made of the receipt and entry of the amendment filed on August 26, 2026, wherein independent claim 1 is amended to recite combination of specific ingredients in the tablet core, isolation layer and enteric layer with particular range of amount/concentration and/or ratio thereof. Status of Claims Claims 1, 9-12, 14-17, 19 and 22 are pending and under examination in this office action. Response to Arguments Applicant's Remarks filed August 26, 2026 have been fully considered. Any objection and rejection found in the previous Office Action and not repeated herein have been withdrawn in view of amendment and Applicant’s remarks .The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. There are no working telephone number or email address to reach the attorney of record, Charles Liu. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter. Claim 1 is amended to recite multi-layer enteric composition of tetramethylpyrazine nitrone (TBN), (cis)-2-methyl-N-[(3,5,6-trimethylpyrazin-2-yl)methylene]-2-propylamine oxide, comprising tablet core, isolation layer and enteric layer, comprising sodium bicarbonate as alkalizing agent, magnesium stearate as lubricant and other specific ingredients as binders, fillers, disintegrant, plasticizers, coating material, anti-sticking agent, with particular range of amount/concentration or ratio thereof (See Examples 13-25). The closest prior art are Wang (US 2011/0034485 A1) and GAO (CN 101269049 A). Wang ’485 discloses preparation of tetramethylpyrazine nitrone/TBN, pharmaceutic composition (e.g. tablet ) comprising TBN and method of treating neurological or cardiovascular diseases (e.g. stroke) with TBN. Wang ’485 is silent about enteric tablet comprising TBN in combination with instantly recited ingredients. GAO teaches enteric tablet for a similar compound TMPP without nitrone group. GAO is silent about the isolation layer between the tablet core and the enteric layer, and moisture barrier that’s critical for the stability of TBN. Instant claimed multi-layered enteric TBN composition comprising sodium bicarbonate as alkalizing agent and an isolation layer is stable for three month at 40º C (See Table 8) and has satisfactory dissolution profile (See Table 9) and pharmacokinetic parameter in animal model (See Table 10-13). Thus, claims 1, 11, 12, 14-17 and 19 are not obvious in light of prior art. Rejection of claims 1, 4, 6, 8 and 11-21 under 35 U.S.C. 103 as being unpatentable over Wang et al (US 2011/0034485 A1), in view of GAO et al. (CN 101269049 A), Oliveira Varum et al.( US 20140056980 A1) and Zhong et al. (CN 101987081B) is withdrawn. Election/Restrictions Applicant elected, with traverse, Group I invention of TBN pharmaceutical composition, and the following species: sodium bicarbonate for alkalizing agent, hydroxypropyl cellulose for binder, Crospovidone for disintegrant, mannitol for filler, magnesium stearate for lubricant, triethyl citrate for plasticizer, titania for opaquer, and talc for anti-sticking agent, and methacrylic acid-ethyl acrylate copolymer for coating material, in the reply filed 10/15/2024. The traversal is on the ground(s) that "ligustrazine phosphate in Gao is a different compound from TBN " and “the composition of the tablet core and coating in Gao is different from those of this application…”. The requirement is made FINAL in office action mailed on December 17, 2024. Claims 9-10 were withdrawn as being directed to non-elected inventions, there being no allowable generic or linking claim. Claim 1 amended on August 26, 2026 is now directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claims 9 and 10, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104. Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on August 14, 2024 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Priority This application 17/434,624 filed on 08/27/2021 is 371 of PCT/CN2019/098709 filed on 07/31/2019 and claims benefit of CHINA 201910143739.0 filed on 02/27/2019. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Claim 10 is rejected under 35 U.S.C. 112(a) because the specification, while being enabling for a method of treating certain neurological disease, cardiovascular disease or cerebrovascular disease (e.g. stroke ) with instantly claimed TBN composition of claim 1, does not reasonably provide enablement for a method of treating all neurological disease, cardiovascular disease and cerebrovascular disease with instantly claimed TBN composition of claim 1. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. To be enabling, the specification must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993). The determination that "undue experimentation" would have been needed to practice the claimed invention in full scope is not a single, simple factual determination. As stated in the MPEP 2164.01(a), “There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue." In In re Wands, 8 USPQ2d 1400 (1988), factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have need described. They are: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. These factors are always applied against the background understanding that scope of enablement varies inversely with the degree of unpredictability involved. Keeping that in mind, the Wands factors are relevant to the instant application for the following reasons: The Breadth of The Claims/ Nature of The Invention Claim 10 recites a method of treating a neurological disease, a cardiovascular disease, or a cerebrovascular disease comprising administering the pharmaceutical composition according to claim 1. The neurological disease, cardiovascular disease, or cerebrovascular disease genus comprise vast variety of disease/disorder that have different symptoms, different etiology, different subject and different treatment, etc. Thus, the scope of claim 10 drawn to a method of treating neurological disease, cardiovascular disease, or cerebrovascular disease genus is extremely broad. The complex nature of the subject matter of this invention is greatly exacerbated by the breadth of the claims. The State of the Prior Art and the Predictability or Lack Thereof in the Art It is well known in the prior art that treatment of neurological disease, cardiovascular disease, or cerebrovascular disease are challenging. For example, agitation/dementia in Alzheimer’s disease is very complex and highly unpredictable to treat. Ringman (2019) reviews management of agitation in persons with dementia with a focus on pharmacological treatment of Alzheimer’s patients(Current Treatment Options Neurol (2019) 21: 30, DOI 10.1007/s11940-019-0572-3, “Treatment Options for Agitation in Dementia”). Ringman teaches “Associated with advancing neurodegenerative disease, agitation is arguably the most disrupting and challenging symptom to patients, family members, and professional and non-professional caregivers. Despite its importance, currently available pharmacological and non-pharmacological interventions have limited and unreliable efficacy. Barriers to the development of effective treatments include but are not limited to difficulties defining and measuring agitation in dementia, appropriate design of clinical trials, the frailty of the intended population, and perhaps the fundamental intractability of the problem” (See page 2/14, left column, Introduction). Ringman further teaches “Considering the heterogeneity of patients and their comorbidities as well as the specific nature of their “agitation”, there is no “one-size fits all” approach to agitation in AD” and “consistently effective and safe pharmacologic interventions are still lacking” (See Abstract). More generally, the invention is directed toward medicine and is therefore physiological in nature. It is well established that “the scope of enablement varies inversely with the degree of unpredictability of the factors involved,” and physiological activity (e.g., cancer prevention) is generally considered an unpredictable factor. See In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). The Amount of Direction Present and Presence or Absence of Working Examples Instant specification discloses preparation of enteric-coated TBN composition as recited in claim 1 (See Examples 13-25) and pharmacokinetic profile thereof (See Tables 11-13). Instant spec discloses TBN has improved antioxidation ability while maintaining the thrombolytic ability, and can be used for the treatment of neurodegenerative diseases, cardiovascular and cerebrovascular diseases, etc. e.g. Alzheimer’s Disease, stroke, etc. (See [0004] [0043]-[0044]). However, instant specification does not disclose any efficacy data wherein instantly claimed TBN composition was administered to a subject for treating any disease/disorder. Instant specification does not disclose any assay for treating a disease/ disorder with TBN composition. instant specification does not disclose any working example wherein instantly claimed TBN composition was administered to a subject for treating disease/disorder. Although prior art Wang ’485 teaches a method for treating cerebrovascular disease (e.g. stroke ) with TBN, in absence of sufficient assay/efficacy data disclosed by instant specification, an ordinary skilled in the art would not know if instant claimed TBN composition would be effective for treating the vast variety of neurodegenerative diseases, cardiovascular and cerebrovascular disease as recited in claim 9. The level of one of ordinary skill in the art The level of skill required to make and/or use the instant invention would likely require professional experience conducting research in the art (e.g., medicine, pharmaceutical science, biology, biochemistry, medicinal chemistry, etc.) as well as an advanced educational degree (e.g., M.D. and/or Ph.D.) commensurate in level with the advanced techniques involved in the preparation and/or use of the instant invention. The quantity of experimentation needed An unduly extensive amount of experimentation would be required for one of ordinary skill in the art to use the claimed invention in full scope. Working examples for treating different neurological disease, cardiovascular disease, or cerebrovascular disease would be needed to establish/validate the full scope of claim 9. The therapeutically effective amount for treating different disease/disorder may vary depending on many factors, such the subjects being treated, the disease condition, administration route and intended treatment outcome, etc. Therefore, it would be a great burden for one of ordinary skill in the art to carry out undue experimentation to use the claimed invention for treating neurological disease, cardiovascular disease, or cerebrovascular disease genus in full scope. Conclusion MPEP 2164.01(a) states, “A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557,1562,27 USPQ2d 1510, 1513 (Fed. Cir. 1993).” That conclusion is clearly justified here with respect to the claimed method of treating neurological disease, cardiovascular disease, or cerebrovascular disease genus with instantly claimed enteric-coated TBN composition in view of the analysis above pursuant to In re Wands. In other words, one skilled in the art could not practice the claimed invention in full scope without undue experimentation. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 9 and 22 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 9 is drawn to a method of preparing a pharmaceutical composition comprising TBN, or a salt or a hydrate thereof according to claim 1, comprising two steps: (1) sieving the active ingredient TBN or a pharmaceutically acceptable salt or hydrate thereof, and an alkalizing agent and/or a binder and/or a disintegrant and/or a filler, directly mixing or mixing and then granulating, optionally mixing with a lubricant, and tableting to obtain tablet cores; and (2) coating the tablet core in Step (1) with an enteric layer at 40-50º C and removing to obtain a TBN enteric-coated tablet; First, the recitation of “directly mixing or mixing and then granulating, optionally mixing” in step 1) is confusing. It’s not clear how the ingredients in the tablet core are mixed. The recitation of “removing” without any substance in Step 2) is incomplete for omitting essential substance. Second, claim 9 does not recite how the enteric layer comprising variety of ingredients, e.g. opaquer , coating agent, plasticizer and/or an anti-sticking agent is prepared. More important, claim 9 omits the essential step of preparing isolation layer between the tablet core and enteric layer as recited in claim 1, which is essential/crucial for the stability of instantly claimed enteric composition of TBN. Accordingly, claim 9 fails to clearly define the steps required to produce the claimed multi-layer enteric composition of TBN. Claim 22 contains the trademark/trade name Opadry®. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name Opadry® is used to identify/describe a coating system comprising different polymers, plasticizers and pigments. Accordingly, the identification/description of the coating system in claim 22 is indefinite. Conclusion Claims 1, 11, 12, 14-17 and 19 are allowable. Claims 9-10 and 22 are rejected. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LIYUAN MOU whose telephone number is (571)270-1791. The examiner can normally be reached Mon-Fri 9:00-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached on (571)272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LIYUAN MOU/ Examiner, Art Unit 1628 /JARED BARSKY/Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Show 2 earlier events
Apr 16, 2025
Response Filed
Oct 01, 2025
Final Rejection mailed — §112
Dec 29, 2025
Response after Non-Final Action
Mar 19, 2026
Request for Continued Examination
Apr 01, 2026
Response after Non-Final Action
Jul 13, 2026
Non-Final Rejection mailed — §112
Aug 26, 2026
Response Filed
Oct 16, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767675
STRUCTURED MOLECULAR VECTORS FOR ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF
5y 2m to grant Granted Oct 20, 2026
Patent 12758544
New Pharmaceutical Formulation
4y 8m to grant Granted Oct 13, 2026
Patent 12758487
METHODS FOR DOSE INITIATION OF ARIPIPRAZOLE TREATMENTS
2y 4m to grant Granted Oct 13, 2026
Patent 12708604
Lyophilized preparation of prostaglandin E1 methyl ester for injection and production and use thereof
5y 2m to grant Granted Aug 18, 2026
Patent 12692254
BENZIMIDAZOLE INHIBITORS OF PAD ENZYMES
5y 5m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
44%
Grant Probability
99%
With Interview (+59.9%)
3y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 121 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month